Jasmina Smajic
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jasmina Smajic has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Alma Trnacevic
Clinic for Infectious Diseases, University Clinical Center Tuzla, 75 000 Tuzla, Bosnia and Herzegovina
1 shared publication - Amra Adrovic
Department of Pediatric Rheumatology, Istanbul University-Cerrahpasa
1 shared publication - Ayhan Olcay
Bogazici University Center for Targeted Therapy Technologies, Istanbul, Turkey
1 shared publication - Ena Smajic
University Clinical Center Tuzla, Bosnia and Herzegovina
1 shared publication - Fatima Iljazagic Halilovic
University Clinical Center Tuzla, Bosnia and Herzegovina
1 shared publication - Kamber Kaşali
Atatürk Universitesi
1 shared publication
Latest Publications
- Open Access
A Retrospective Look at Early COVID-19 Treatment and Outcomes in Two Tertiary Centers in Türkiye and Bosnia & Herzegovina
During the early months of the COVID-19 pandemic, treatment protocols varied substantially among countries and even between hospitals. This study compared the clinical characteristics, management strategies, and outcomes of hospitalized COVID-19 patients treated in tertiary centers in Türkiye and Bosnia and Herzegovina. We retrospectively analyzed 1338 adults hospitalized with laboratory-confirmed SARS-CoV-2 infection: 657 patients in Tuzla (Bosnia and Herzegovina, June–December 2020) and 681 in İstanbul (Turkiye, April–May 2020). Demographic, clinical, and laboratory data, treatment details (including favipiravir use), need for invasive or non-invasive mechanical ventilation, and in-hospital mortality were extracted from medical records. Patients in Bosnia and Herzegovina were older (61.6 ± 14.4 vs. 56.9 ± 15.8 years; p < 0.001) and had longer hospital stays (9.0 ± 5.5 vs. 7.7 ± 6.1 days; p < 0.001). In the Bosnian cohort, leukocyte, neutrophil, platelet, ferritin, CRP, troponin, creatinine, AST, and ALT levels were significantly higher, whereas hemoglobin and D-dimer levels were lower. The need for ventilatory support was greater in Bosnia and Herzegovina (15.1% vs. 12.2%, p < 0.001), and overall mortality was higher (25.7% vs. 9.3%, p < 0.001). No mortality difference was observed between patients treated and not treated with favipiravir. Despite similar inclusion criteria, patients in Bosnia and Herzegovina exhibited more severe disease, greater organ involvement, and higher mortality than those in Turkiye. Favipiravir use did not influence survival. Inter-country comparisons highlight how differing patient profiles and treatment protocols may impact COVID-19 outcomes; however, interpretation should consider that the two centers contributed data from different phases of the 2020 pandemic, and that country-level differences in circulating variants, healthcare capacity, hospital strain, and evolving clinical guidelines may also have influenced the observed patterns.
Open AccessA Retrospective Look at Early COVID-19 Treatment and Outcomes in Two Tertiary Centers in Türkiye and Bosnia & Herzegovina
During the early months of the COVID-19 pandemic, treatment protocols varied substantially among countries and even between hospitals. This study compared the clinical characteristics, management strategies, and outcomes of hospitalized COVID-19 patients treated in tertiary centers in Türkiye and Bosnia and Herzegovina. We retrospectively analyzed 1338 adults hospitalized with laboratory-confirmed SARS-CoV-2 infection: 657 patients in Tuzla (Bosnia and Herzegovina, June–December 2020) and 681 in İstanbul (Turkiye, April–May 2020). Demographic, clinical, and laboratory data, treatment details (including favipiravir use), need for invasive or non-invasive mechanical ventilation, and in-hospital mortality were extracted from medical records. Patients in Bosnia and Herzegovina were older (61.6 ± 14.4 vs. 56.9 ± 15.8 years; p < 0.001) and had longer hospital stays (9.0 ± 5.5 vs. 7.7 ± 6.1 days; p < 0.001). In the Bosnian cohort, leukocyte, neutrophil, platelet, ferritin, CRP, troponin, creatinine, AST, and ALT levels were significantly higher, whereas hemoglobin and D-dimer levels were lower. The need for ventilatory support was greater in Bosnia and Herzegovina (15.1% vs. 12.2%, p < 0.001), and overall mortality was higher (25.7% vs. 9.3%, p < 0.001). No mortality difference was observed between patients treated and not treated with favipiravir. Despite similar inclusion criteria, patients in Bosnia and Herzegovina exhibited more severe disease, greater organ involvement, and higher mortality than those in Turkiye. Favipiravir use did not influence survival. Inter-country comparisons highlight how differing patient profiles and treatment protocols may impact COVID-19 outcomes; however, interpretation should consider that the two centers contributed data from different phases of the 2020 pandemic, and that country-level differences in circulating variants, healthcare capacity, hospital strain, and evolving clinical guidelines may also have influenced the observed patterns.
- Open Access
- 28 April 2025
- Published by MDPI AG in Preprints.org
Can the cHIS Score Predict ICU Mortality and Mechanical Ventilation in Critically Ill COVID-19 Patients?!
Objectives: Hyperinflammatory syndrome in COVID-19 (cHIS) is a severe immune dysregulation characterized by excessive cytokine release, contributing to adverse outcomes. The cHIS score has been proposed as a prognostic tool for identifying patients at risk of poor outcomes. Aim of this study was to validate the predictive accuracy of the cHIS score for mechanical ventilation requirements and ICU mortality in critically ill COVID-19 patients. Methods: This single-center, retrospective observational study included 85 critically ill COVID-19 patients admitted to the Intensive Care Unit of the University Clinical Center Tuzla between June 2020 and October 2020. Patients were stratified into groups on the basis of cHIS scores (< 3 and ≥3). cHIS score parameters, mechanical ventilation requirements and ICU mortality were analyzed. Logistic re-gression models and the area under the receiver operating characteristic (AUROC) curves were em-ployed to assess the predictive validity of the cHIS score. Results: Among 85 patients, 60% had cHIS scores ≥3. A cHIS score ≥3 was associated with in-creased risk of mechanical ventilation and ICU mortality. The sensitivity and specificity for predicting ICU mortality were 76% and 66%, respectively, while for mechanical ventilation, sensitivity was 73% and specificity 65%. Multivariate analysis confirmed the cHIS score as an independent predictor of both outcomes after adjusting for age and comorbidities. Conclusion: The cHIS score reliably predicts ICU mortality and mechanical ventilation in critically ill COVID-19 patients, supporting early risk stratification and targeted interventions to improve patient outcomes.
- 28 April 2025
- Published by MDPI AG in Preprints.org
Open AccessCan the cHIS Score Predict ICU Mortality and Mechanical Ventilation in Critically Ill COVID-19 Patients?!
Objectives: Hyperinflammatory syndrome in COVID-19 (cHIS) is a severe immune dysregulation characterized by excessive cytokine release, contributing to adverse outcomes. The cHIS score has been proposed as a prognostic tool for identifying patients at risk of poor outcomes. Aim of this study was to validate the predictive accuracy of the cHIS score for mechanical ventilation requirements and ICU mortality in critically ill COVID-19 patients. Methods: This single-center, retrospective observational study included 85 critically ill COVID-19 patients admitted to the Intensive Care Unit of the University Clinical Center Tuzla between June 2020 and October 2020. Patients were stratified into groups on the basis of cHIS scores (< 3 and ≥3). cHIS score parameters, mechanical ventilation requirements and ICU mortality were analyzed. Logistic re-gression models and the area under the receiver operating characteristic (AUROC) curves were em-ployed to assess the predictive validity of the cHIS score. Results: Among 85 patients, 60% had cHIS scores ≥3. A cHIS score ≥3 was associated with in-creased risk of mechanical ventilation and ICU mortality. The sensitivity and specificity for predicting ICU mortality were 76% and 66%, respectively, while for mechanical ventilation, sensitivity was 73% and specificity 65%. Multivariate analysis confirmed the cHIS score as an independent predictor of both outcomes after adjusting for age and comorbidities. Conclusion: The cHIS score reliably predicts ICU mortality and mechanical ventilation in critically ill COVID-19 patients, supporting early risk stratification and targeted interventions to improve patient outcomes.